Research Article
Incidence of Hyperlipidemia among Adults Initiating Antiretroviral Therapy in the HIV Outpatient Study (HOPS), USA, 2007–2021
Table 2
Hyperlipidemia1 incidence rates (per 100 person years) and rate ratios among ART-naïve adults with HIV initiating ART in the HIV Outpatient Study, USA, 2007–2021 (N = 349).
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABC, abacavir; ART, antiretroviral therapy; aRR, adjusted rate ratios; BMI, body mass index; CI, confidence interval; DTG, dolutegravir; RAL, raltegravir; INSTIs, integrase strand transfer inhibitors; IR, incidence rate; NA, not applicable; PI, protease inhibitor; RR, rate ratio; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate. 1Hyperlipidemia is defined based on diagnosis, starting antilipidemic treatments, non-HDL-C ≥160 mg/dL, LDL-C ≥130 mg/dL, triglycerides ≥150 mg/dL, or total cholesterol ≥200 mg/dL. 2 values were derived from the chi-squared test. 3aRR was derived from Poisson regression, and the model was adjusted for age/10 years, race/ethnicity, type of the HOPS site, and TDF use. The 4INSTI-others group included bictegravir and elvitegravir. |